Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $9.8 million.

  • Fennec Pharmaceuticals' Total Current Liabilities rose 3201.08% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 3201.08%. This contributed to the annual value of $6.9 million for FY2024, which is 839.4% down from last year.
  • Fennec Pharmaceuticals' Total Current Liabilities amounted to $9.8 million in Q3 2025, which was up 3201.08% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Total Current Liabilities ranged from a high of $9.8 million in Q1 2024 and a low of $848000.0 during Q2 2021
  • Over the past 5 years, Fennec Pharmaceuticals' median Total Current Liabilities value was $4.3 million (recorded in 2022), while the average stood at $5.3 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 7341.69% in 2021, then skyrocketed by 25813.68% in 2022.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Total Current Liabilities stood at $2.0 million in 2021, then surged by 128.85% to $4.6 million in 2022, then soared by 63.88% to $7.6 million in 2023, then dropped by 8.39% to $6.9 million in 2024, then soared by 41.86% to $9.8 million in 2025.
  • Its Total Current Liabilities stands at $9.8 million for Q3 2025, versus $8.4 million for Q2 2025 and $8.4 million for Q1 2025.